These findings collectively suggest that Hu-B03 CAR-T cells maintained strong antitumor efficacy against CD155+ AML and NSCLC in vitro and in vivo while potentially reducing immunogenicity, thereby enhancing their suitability for clinical applications. This evidence concerns the gene PVR and non-small cell lung carcinoma.